These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 21119195

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bosentan for the treatment of portopulmonary hypertension.
    Tempe DK, Datt V, Datta D.
    Ann Card Anaesth; 2008; 11(2):139-40; author reply 140. PubMed ID: 18603763
    [No Abstract] [Full Text] [Related]

  • 3. Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?
    Brancaccio G, Toscano A, Bevilacqua M, Di Chiara L, Parisi F.
    Pediatr Transplant; 2007 Feb; 11(1):110-2. PubMed ID: 17239133
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combination drug therapy in the management of pulmonary arterial hypertension.
    Kayser SR.
    Prog Cardiovasc Nurs; 2005 Feb; 20(4):177-82. PubMed ID: 16276142
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value.
    Hoeper MM.
    Eur Respir J; 2007 Mar; 29(3):432-4. PubMed ID: 17329488
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [The combined use of sildenafil with epoprostenol in a patient with primary pulmonary hypertension].
    Kayikçioğlu M, Can LH, Payzin S, Kültürsay H, Soydan I.
    Anadolu Kardiyol Derg; 2002 Sep; 2(3):262-4. PubMed ID: 12223337
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM.
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [Abstract] [Full Text] [Related]

  • 15. Consecutive use of sildenafil and bosentan for the treatment of pulmonary arterial hypertension associated with collagen vascular disease: sildenafil as reliever and bosentan as controller.
    Kamata Y, Iwamoto M, Minota S.
    Lupus; 2007 Apr; 16(11):901-3. PubMed ID: 17971364
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, Hassoun PM.
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Directing therapy in pulmonary arterial hypertension using a target 6 min walk distance.
    Porhownik NR, Myers R, Bshouty Z.
    Can Respir J; 2013 Mar; 20(2):111-5. PubMed ID: 23616968
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.